Deutsche Bank Starts Idenix Pharmaceuticals Inc. (IDIX) at Buy
Tweet Send to a FriendGet Alerts IDIX Hot Sheet
Price: $5.20 +0.39%
Rating Summary:
5 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 24 | Down: 17 | New: 24
Rating Summary:
5 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 24 | Down: 17 | New: 24
Trade IDIX Now!
Deutsche Bank initiates Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) with a Buy rating and price target of $7.00, citing favorable risk/reward.
"We think current levels reflect a worst case (only royalties & no pipeline)," the analyst comments. "We see an upside case for a re-emerging HCV platform in early '13. We think IDIX is high risk due to lack of visibility, but also high reward over next 12 mos."
"Our review of the in vitro data suggests that IDIX & BMS nukes differ significantly. 5 differences: 1) pro-drug structure 2) liver targeting 3) different PK/PD 4) off target cell activity 5) by-products."
The firm sees IDIX FVs of $7-9/sh if IDX-184 comes off hold. In addition the think the announcement of a clinical collabo with another drug class represents another upside catalyst in 1H13
For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.
Shares of Idenix Pharmaceuticals Inc. closed at $4.52 yesterday, with a 52 week range of $3.35-$15.25.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"We think current levels reflect a worst case (only royalties & no pipeline)," the analyst comments. "We see an upside case for a re-emerging HCV platform in early '13. We think IDIX is high risk due to lack of visibility, but also high reward over next 12 mos."
"Our review of the in vitro data suggests that IDIX & BMS nukes differ significantly. 5 differences: 1) pro-drug structure 2) liver targeting 3) different PK/PD 4) off target cell activity 5) by-products."
The firm sees IDIX FVs of $7-9/sh if IDX-184 comes off hold. In addition the think the announcement of a clinical collabo with another drug class represents another upside catalyst in 1H13
For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.
Shares of Idenix Pharmaceuticals Inc. closed at $4.52 yesterday, with a 52 week range of $3.35-$15.25.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Global Equities Starts Tesla Motors (TSLA) at Overweight
- Cowen Starts Teradata (TDC) at Underperform
- UPDATE: Oppenheimer Upgrades GameStop (GME) to Outperform
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Deutsche Bank
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
